Targeted adjuvant: First Data on Alectinib in Patients with operable ALK plus NSCLC

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ESMO 2023 Adjuvant alectinib in operable ALK plus NSCLC, precision medicine in CUP syndrome
    Freyer, Martina
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (1-2)
  • [2] Alectinib superior to chemotherapy in advanced ALK plus NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (06): : E285 - E285
  • [3] Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now
    Passaro, Antonio
    Peters, Solange
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1325 - 1327
  • [4] Adjuvant alectinib improves outcomes in ALK-mutant NSCLC
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (07) : 484 - 484
  • [5] Updated Data from JP28927 Study of Alectinib in ALK plus NSCLC Patients with or without History of ALK Inhibitor Treatment
    Hotta, Katsuyuki
    Hida, Toyoaki
    Nakagawa, Kazuhiko
    Seto, Takashi
    Satouchi, Miyako
    Nishio, Makoto
    Murakami, Haruyasu
    Ohe, Yuichiro
    Takeda, Koji
    Yoshimoto, Takuya
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S648 - S648
  • [6] ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK plus NonSmall Cell Lung Cancer (NSCLC)
    Horinouchi, H.
    Solomon, B. J.
    Wu, Y. L.
    Barlesi, F.
    Nishio, M.
    Ahn, J. S.
    Lee, D. H.
    Lee, J. S.
    Zhong, W.
    Hochmair, M.
    Bondarenko, I.
    Planchard, D.
    Rittmeyer, A.
    Ding, B.
    Ruf, T.
    Adler, L.
    Scalori, A.
    Dziadziuszko, R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S39 - S39
  • [7] Deciphering the mechanisms of environmentally mediated Alectinib resistance in ALK plus NSCLC
    Kumar, Pragya
    Turati, Virginia
    Marusyk, Andriy
    CANCER RESEARCH, 2022, 82 (10)
  • [8] Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK plus NSCLC
    Lee, J. M.
    Sepesi, B.
    Toloza, E. M.
    Lin, J.
    Pass, H. I.
    Johnson, B. E.
    Heymach, J. V.
    Johnson, M. L.
    Ding, B.
    Schulze, K.
    Zhu, Q.
    Ngiam, C.
    Brandao, E.
    Bara, I.
    Chaft, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S233 - S234
  • [9] NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IBIII ALK plus NSCLC
    Lee, J. M.
    Toloza, E. M.
    Pass, H. I.
    Johnson, B. E.
    Heymach, J. V.
    Sholl, L.
    Saqi, A.
    Travis, W. D.
    Wistuba, I.
    Lin, J.
    Kris, M. G.
    Spira, A. I.
    Shu, C. A.
    Saltos, A. N.
    Ding, B.
    Schulze, K.
    Zhu, Q.
    Ngiam, C.
    Bara, I.
    Chaft, J. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S297 - S298
  • [10] Cost Analysis of the Management of CNS Metastases in Patients with Advanced ALK plus NSCLC: Alectinib vs Crizotinib
    Massuti, B.
    Lazaro, M.
    Isla, D.
    Gordo, R.
    Ruiz De Alda, L.
    Ortega, N.
    Oyaguez, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S856 - S856
12345